Two-dose basiliximab compared with two-dose daclizumab in renal transplantation: A clinical study

Clinical Transplantation

Volumn 20, Issue 3, 2006, Pages 325-329

  Lin, Minzhuan ^a,b   Ming, Aimin ^a,b   Zhao, Ming ^a,b  

^a Hospital of Guangzhou Economic and Technological Development District   (China)

^b SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Basiliximab; Daclizumab; IL 2; IL 2receptor antagonist; Renal transplantation

Indexed keywords

BASILIXIMAB; CORTICOSTEROID; CYCLOSPORIN; DACLIZUMAB; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PREDNISOLONE; STEROID;

ACUTE GRAFT REJECTION; ADULT; ARTICLE; CADAVER DONOR; CD25+ T LYMPHOCYTE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG FATALITY; FEMALE; FLOW CYTOMETRY; GRAFT FAILURE; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INCIDENCE; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; LUNG INFECTION; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECIPIENT;

ADULT; ANTIBODIES, MONOCLONAL; CYCLOSPORINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GRAFT REJECTION; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; MALE; MYCOPHENOLIC ACID; RECOMBINANT FUSION PROTEINS; TACROLIMUS;

EID: 33646711624     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2005.00488.x     Document Type: Article

References (20)

1. Pirsch JD, Ploeg RJ, Gange S et al. Determinants of graft survival after renal transplantation. Transplantation 1996: 61: 1581.
2. Flechner SM, Modlin CS, Serrano DP et al. Determinants of chronic renal allograft rejection in cyclosporine-treated recipients. Transplantation 1996: 62: 1235.
3. Hariharan S, Johnson CP, Bresnahan BA, Taranto SE, Mc Intosh MJ, Stablein D. Improved graft survival after renal transplantation in the United States, 1988 to 1996. N Eng J Med 2000: 342: 605.
4. Meier-Kriesche H-U, Schold JD, Srinivas TR, Kaplan B. Lack of improvement in renal allograft survival despite a marked decrease in acute rejection rates over the most recent era. Am J Transplant 2004: 4: 378.
5. Bunnapradist S, Takemoto SK. Multivariate analyses of antibody induction therapies. Chapter 32. Multivariate analyses of antibody induction therapy. In: Cecka JM, T erasaki PI, eds. Clinical Transplants. Los Angeles: UCLA Immunogenetics Center, 2003.
6. Webster AC, Playford EG, Higgins G, Chapman JR, Craig JC. Interleukin 2 receptor antagonists for renal transplant recipients: A meta-analysis of randomized trials. Transplantation 2004: 77: 166.
7. Adu D, Cockwell P, Ives NJ, Shaw J, Wheatley K. Interleukin-2 receptor monoclonal antibodies in renal transplantation: Meta-analysis of randomised trials. Br Med J 2003: 326-789.
8. Cherikh WS, Kauffman HM, Mc Bride MA, Maghirang J, Swinnen LJ, Hanto DW. Association of the type of induction immunosuppression with posttransplant lymphoproliferative disorder, graft survival, and patient survival after primary kidney transplantation. Transplantation 2003: 76: 1289.
9. Simulect® (basiliximab). Prescribing information. http://www.pharma.us.novartis.com/product/pi/pdf/simulect.pdf. Date of access 21 December 2004.
10. Zenapax® (daclizumab). Prescribing information. http://www.rocheusa.com/products/zenapax/pi.pdf. Date of access 21 December 2004.
11. Nair MP, Nampoory MRN, Johny KV et al. Induction immunosuppression with interleukin-2 receptor antibodies (basiliximab and daclizumab) in renal transplant recipients. Transplant Proc 2001: 33: 2767.
12. Soltero L, Carbajal H, Sarkissian N et al. A truncated-dose regimen of daclizumab for prevention of acute rejection in kidney transplant recipients: A single-center experience. Transplantation 2004: 78: 1560.
13. Ekberg H, Persson NH, Kallen R, Gul-Baykurt N. Two doses of daclizumab in conjunction with low-dose cyclosporine, mycophenolate mofetil and steroids resulted in a low incidence of acute rejection after renal transplantation. Scand J Immunol 2003: 58: 670.
14. Stratta RJ, Alloway RR, Lo A, Hodge EE for the PIVOT Study Group. One-year outcomes in simultaneous kidney-pancreas transplant recipients receiving an alternative dosing regimen of daclizumab. Transplant Proc 2004: 36: 1080.
15. Niemeyer G, Kock M, Light S, Kuse ER, Nashan B. Long-term safety, tolerability and efficacy of daclizumab (Zenapax®) in a two-dose regimen in liver transplant recipients. Am J Transplant 2002: 2: 454.
16. Sellers MT, Mc Guire BM, Haustein SV, Bynon JS, Hunt SL, Eckhoff DE. Two-dose daclizumab induction therapy in 209 liver transplants: A single-center analysis. Transplantation 2004: 78: 1212.
17. Eckhoff DE, Mc Guire B, Sellers M et al. The safety and efficacy of a two-dose daclizumab (Zenapax) induction therapy in liver transplant recipients. Transplantation 2000: 69: 1867.
18. Joyal D, Cantarovich M, Cecere R, Giannetti N. Early experience with two-dose daclizumab in the prevention of acute rejection in cardiac transplantation. Clin Transplant 2004: 18: 493.
19. Racusen LC, Solez K, Colvin RB et al. The Banff 97 working classification of renal allograft pathology. Kidney Int 1999: 55: 713.
20. Vincenti F, Pace D, Birnbaum J, Lantz M. Pharmacokinetic and pharmacodynamic studies of one or two doses of daclizumab in renal transplantation. Am J Transplant 2003: 3: 50.